Targeted Radionuclide Therapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2013 Nov 12

PMID 24213114

Citations 34

Authors

Devrim Ersahin

Indukala Doddamane

David Cheng

Affiliations

Soon will be listed here.

Abstract

Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. Several different radiopharmaceuticals are currently being used by various administration routes and targeting mechanisms. This article aims to briefly review the current status of targeted radiotherapy as well as to outline the advantages and disadvantages of radionuclides used for this purpose.

Citing Articles

Radiopharmaceuticals and their applications in medicine.

Zhang S, Wang X, Gao X, Chen X, Li L, Li G Signal Transduct Target Ther. 2025; 10(1):1.

PMID: 39747850 PMC: 11697352. DOI: 10.1038/s41392-024-02041-6.

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to Lutetium.

Ramonaheng K, Qebetu M, Ndlovu H, Swanepoel C, Smith L, Mdanda S Front Nucl Med. 2024; 4:1355912.

PMID: 39355215 PMC: 11440950. DOI: 10.3389/fnume.2024.1355912.

Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.

Winter R, Amghar M, Wacker A, Bakos G, Tas H, Roscher M Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204136 PMC: 11359268. DOI: 10.3390/ph17081031.

Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy.

Onoue R, Watanabe H, Ono M ACS Pharmacol Transl Sci. 2024; 7(5):1395-1403.

PMID: 38751619 PMC: 11091974. DOI: 10.1021/acsptsci.4c00035.

Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [Lu]Lu-DOTATATE radiopharmaceutical therapy.

Mansouri Z, Salimi Y, Akhavanallaf A, Shiri I, Teixeira E, Hou X Eur J Nucl Med Mol Imaging. 2024; 51(6):1516-1529.

PMID: 38267686 PMC: 11043201. DOI: 10.1007/s00259-024-06618-9.

References

de Labriolle-Vaylet C, Cattan P, Sarfati E, Wioland M, Billotey C, BROCHERIOU C . Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery. Clin Cancer Res. 2000; 6(2):363-71. View

Kalinowski M, Dressler M, Konig A, El-Sheik M, Rinke A, Hoffken H . Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. 2009; 79(3):137-42. DOI: 10.1159/000209849. View

Witzig T . Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Semin Oncol. 2004; 30(6 Suppl 17):11-6. DOI: 10.1053/j.seminoncol.2003.10.007. View

Krenning E, Bakker W, Breeman W, Koper J, Kooij P, Ausema L . Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989; 1(8632):242-4. DOI: 10.1016/s0140-6736(89)91258-0. View

Cardarelli P, Quinn M, Buckman D, Fang Y, Colcher D, King D . Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002; 51(1):15-24. PMC: 11032933. DOI: 10.1007/s00262-001-0247-1. View

Castellani M, Seregni E, Maccauro M, Chiesa C, Aliberti G, Orunesu E . MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?. Q J Nucl Med Mol Imaging. 2008; 52(4):430-40. View

Chrisoulidou A, Kaltsas G, Ilias I, Grossman A . The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007; 14(3):569-85. DOI: 10.1677/ERC-07-0074. View

Safford S, Coleman R, Gockerman J, Moore J, Feldman J, Onaitis M . Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer. 2004; 101(9):1987-93. DOI: 10.1002/cncr.20592. View

Witzig T, White C, Wiseman G, Gordon L, Emmanouilides C, Raubitschek A . Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17(12):3793-803. DOI: 10.1200/JCO.1999.17.12.3793. View

10.

Waldherr C, Pless M, Maecke H, Haldemann A, Mueller-Brand J . The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001; 12(7):941-5. DOI: 10.1023/a:1011160913619. View

11.

Kohlfuerst S, Igerc I, Gallowitsch H, Gomez I, Kresnik E, Matschnig S . Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?. Thyroid. 2006; 16(11):1113-9. DOI: 10.1089/thy.2006.16.1113. View

12.

Hall P, Holm L . Cancer in iodine-131 exposed patients. J Endocrinol Invest. 1995; 18(2):147-9. DOI: 10.1007/BF03349726. View

13.

Horning S . Treatment approaches to the low-grade lymphomas. Blood. 1994; 83(4):881-4. View

14.

Kwekkeboom D, de Herder W, Kam B, Van Eijck C, Van Essen M, Kooij P . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13):2124-30. DOI: 10.1200/JCO.2007.15.2553. View

15.

Kwekkeboom D, Krenning E, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder W . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009; 90(2):220-6. DOI: 10.1159/000225951. View

16.

Krenning E, Kooij P, Bakker W, Breeman W, Postema P, Kwekkeboom D . Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994; 733:496-506. DOI: 10.1111/j.1749-6632.1994.tb17300.x. View

17.

Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M . 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers. 2003; 66(6):393-8. DOI: 10.1002/bip.10349. View

18.

Kaminski M, Zelenetz A, Press O, Saleh M, Leonard J, Fehrenbacher L . Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001; 19(19):3918-28. DOI: 10.1200/JCO.2001.19.19.3918. View

19.

Stashenko P, Nadler L, Hardy R, Schlossman S . Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980; 125(4):1678-85. View

20.

Tedder T, Boyd A, Freedman A, Nadler L, Schlossman S . The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985; 135(2):973-9. View